160 related articles for article (PubMed ID: 36185638)
1. The DPY30-H3K4me3 Axis-Mediated PD-L1 Expression in Melanoma.
Zhang Z; Han Y; Sun Q; Wang Y; Sun L
J Inflamm Res; 2022; 15():5595-5609. PubMed ID: 36185638
[TBL] [Abstract][Full Text] [Related]
2. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
[TBL] [Abstract][Full Text] [Related]
3. DPY30 Promotes Proliferation and Cell Cycle Progression of Colorectal Cancer Cells via Mediating H3K4 Trimethylation.
Su WC; Mao XM; Li SY; Luo CY; Fan R; Jiang HF; Zhang LJ; Wang YT; Su GQ; Shen DY
Int J Med Sci; 2023; 20(7):901-917. PubMed ID: 37324189
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases.
Dixit D; Prager BC; Gimple RC; Miller TE; Wu Q; Yomtoubian S; Kidwell RL; Lv D; Zhao L; Qiu Z; Zhang G; Lee D; Park DE; Wechsler-Reya RJ; Wang X; Bao S; Rich JN
Sci Transl Med; 2022 Jan; 14(626):eabf3917. PubMed ID: 34985972
[TBL] [Abstract][Full Text] [Related]
5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
6. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
7. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer.
Zhang J; Zhou Q; Xie K; Cheng L; Peng S; Xie R; Liu L; Zhang Y; Dong W; Han J; Huang M; Chen Y; Lin T; Huang J; Chen X
J Exp Clin Cancer Res; 2021 Jun; 40(1):203. PubMed ID: 34154613
[TBL] [Abstract][Full Text] [Related]
8. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
9. DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.
Zhang L; Zhang S; Li A; Zhang A; Zhang S; Chen L
Int J Mol Med; 2018 Dec; 42(6):3065-3072. PubMed ID: 30221689
[TBL] [Abstract][Full Text] [Related]
10. Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth.
Kwak G; Kim D; Nam GH; Wang SY; Kim IS; Kim SH; Kwon IC; Yeo Y
ACS Nano; 2017 Oct; 11(10):10135-10146. PubMed ID: 28985469
[TBL] [Abstract][Full Text] [Related]
11. DPY30 knockdown suppresses colorectal carcinoma progression via inducing Raf1/MST2-mediated apoptosis.
Jiang H; Su W; Wang H; Luo C; Wang Y; Zhang L; Luo L; Lu Z; Shen D; Su G
Heliyon; 2024 Feb; 10(3):e24807. PubMed ID: 38314299
[TBL] [Abstract][Full Text] [Related]
12. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
13. DPY30 regulates cervical squamous cell carcinoma by mediating epithelial-mesenchymal transition (EMT).
He FX; Zhang LL; Jin PF; Liu DD; Li AH
Onco Targets Ther; 2019; 12():7139-7147. PubMed ID: 31564898
[TBL] [Abstract][Full Text] [Related]
14. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of DPY30 promotes cell proliferation and predicts a poor prognosis in cholangiocarcinoma.
Hong ZF; Zhang WQ; Wang SJ; Li SY; Shang J; Liu F; Shen DY
Biomed Pharmacother; 2020 Mar; 123():109766. PubMed ID: 31846841
[TBL] [Abstract][Full Text] [Related]
16. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.
Gowrishankar K; Gunatilake D; Gallagher SJ; Tiffen J; Rizos H; Hersey P
PLoS One; 2015; 10(4):e0123410. PubMed ID: 25844720
[TBL] [Abstract][Full Text] [Related]
17. The DPY30 subunit in SET1/MLL complexes regulates the proliferation and differentiation of hematopoietic progenitor cells.
Yang Z; Augustin J; Chang C; Hu J; Shah K; Chang CW; Townes T; Jiang H
Blood; 2014 Sep; 124(13):2025-33. PubMed ID: 25139354
[TBL] [Abstract][Full Text] [Related]
18. DPY30 functions in glucose homeostasis via integrating activated histone epigenetic modifications.
Liu B
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):286-290. PubMed ID: 30448059
[TBL] [Abstract][Full Text] [Related]
19. DPY30 regulates pathways in cellular senescence through ID protein expression.
Simboeck E; Gutierrez A; Cozzuto L; Beringer M; Caizzi L; Keyes WM; Di Croce L
EMBO J; 2013 Aug; 32(16):2217-30. PubMed ID: 23872946
[TBL] [Abstract][Full Text] [Related]
20. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
